Glaukos Raises 2026 Sales Forecast and Sets $1 Billion Target for 2027
Glaukos (GKOS) reported a significant third-quarter revenue surge of 58% year-over-year, reaching approximately $211 million. This growth was primarily driven by strong performance in the U.S. Glaucoma segment and a massive 154% increase in Corneal Health sales, fueled by new products like iDose TR and Epioxa. Following these results, the company raised its 2026 sales guidance to a range of $775 million to $785 million. Looking ahead, Glaukos has set a preliminary revenue target of $1 billion for 2027. While GAAP operating income remains thin due to significant legal costs and litigation settlements, the company's high gross margins—reaching approximately 85%—suggest strong scalability as its drug-based product mix expands. The market reacted positively to the guidance, with shares rising over 31%.